ReSync Bio Launches with Funding to Accelerate Drug Discovery
Slice of Healthcare Team
Sep 30, 2024
Key Highlights
- ReSync Bio launches with backing from Caffeinated Capital, Atria Ventures, and angel investors.
- Platform bridges digital and experimental workflows, enabling faster therapeutics development.
- Automates coordination between drug discovery teams and labs to eliminate preclinical bottlenecks.
- Focus on AI-driven drug discovery and efficient preclinical R&D.
Source: Business Wire
Notable Quotes
“ ReSync’s goal is to make therapeutics companies more efficient, so they make decisions faster and ultimately bring therapies to the clinic – and patients – quickly. ReSync is a bridge that synergizes the digital and experimental worlds to help bring therapeutics to the clinic faster. ”
Mihir Trivedi, Founder and CEO at ReSync Bio
“ ReSync is a universal tool that any life sciences company can use to eliminate preclinical bottlenecks and make their data work smarter. ”
Chris Leiter, Partner at Atria Ventures
